Skip to main content
SpringerLink
Log in

GH Receptor Antagonists: Basic Knowledge and Clinical Perspectives

  • Conference paper
Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance

  • 61 Accesses

Abstract

GH is a protein that contains 191 amino acids with two disulfide bonds and four a helices (Abdel-Meguid et al., 1987; de Vos et al., 1992). Its molecular mass is approximately 22 kDa. GH is secreted by the anterior pituitary gland (Theill and Karin, 1993; Ohlsson et al., 1998). GH signal transduction begins with GH binding to a transmembrane GH receptor (Lesniak et al., 1973). GH has two distinct binding domains that bind to two identical GHRs at the cell surface. The initial (high-affinity) binding of the GH binding site I at the GHR is followed by binding at the GH site II, which produces functional receptor dimerization of the two GHRs (de Vos et al., 1992; Carter-Su et al., 2000).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  • Abdel-Meguid S.S., Shieh H.S., Smith W.W., Dayringer H.E., Violand B.N. and Bentie L.A. (1987). Three-dimensional structure of a genetically engineered variant of porcine growth hormone. Proc Natl Acad Sci USA 84, 6434–6437.

    Article  PubMed  CAS  Google Scholar 

  • Bellush L.L., Doublier S., Holland A.N., Striker L.J., Striker G.E. and Kopchick J.J. (2000). Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology, 141, 163–168.

    Article  PubMed  CAS  Google Scholar 

  • Carter-Su C, Rui L. and Herrington J. (2000). Role of the tyrosine kinase JAK2 in signal transduction by growth hormone. Pediatr Nephrol, 14, 550–557.

    Article  PubMed  CAS  Google Scholar 

  • Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H. and Pollak M. (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science, 279, 563–566.

    Article  PubMed  CAS  Google Scholar 

  • Chen N.Y., Chen W.Y., Bellush L., Yang C.W., Striker L.J., Striker G.E. and Kopchick J.J. (1995). Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology, 136, 660–667.

    Article  PubMed  CAS  Google Scholar 

  • Chen N.Y., Chen W.Y. and Kopchick J.J. (1996). A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin. Endocrinology, 137, 5163–5165.

    Article  PubMed  CAS  Google Scholar 

  • Chen W.Y., Chen N., Yun J., Wagner T.E. and Kopchick J.J. (1994). In vitro and in vivo studies of the antagonistic effects of human growth hormone analogs. J Biol Chem, 269, 20806.

    PubMed  CAS  Google Scholar 

  • Chen W.Y., White M.E., Wagner T.E. and Kopchick J.J. (1991a). Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice. Endocrinology, 129, 1402–1408.

    Article  Google Scholar 

  • Chen W.Y., Wight D.C., Mehta B.V., Wagner T.E. and Kopchick J.J. (1991b). Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Mol Endocrinol, 5, 1845–1852.

    Article  Google Scholar 

  • Chen W.Y., Wight D.C., Wagner T.E. and Kopchick J.J. (1990). Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Nat Acad Sci USA, 87, 5061–5065.

    Article  PubMed  CAS  Google Scholar 

  • de Vos A.M., Ultsch M. and Kossiakoff A.A. (1992). Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science, 255, 306–312.

    Article  PubMed  CAS  Google Scholar 

  • Duan H., Dagnaes-Hansen R, Rasmussen L., Friend K.E., Orskov H., Bennet W.F. and Flyvbjerg A. (1999). GH receptor antagonist treatment inhibits growth of human colorectal carcinoma, COLO205 in nude mice. Program of the 5th International Symposium on Insulin-like Growth Factors, Brighton, 1999 (Abstract P13).

    Google Scholar 

  • Flyvbjerg A., Bennett W.F., Rasch R., Kopchick J.J. and Scarlett J.A. (1999). Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes, 48, 377–382.

    Article  PubMed  CAS  Google Scholar 

  • Friend K.E. (2000). Targeting the growth hormone axis as a therapeutic strategy in oncology. Growth Horm IGF Res, 10 (suppl A), S45–S46.

    Article  PubMed  Google Scholar 

  • Friend K.E., Flyvbjerg A., Bennet W.F. and McCutcheon I.E. (2000). The growth hormone receptor antagonist pegvisomant exhibits antitumor activity in multiple preclinical tumor models. Proceedings of the 11th NCI-EORTC-AACR Symposium, Amsterdam, The Netherlands (Abstract 420).

    Google Scholar 

  • Friend K.E., Radinsky R. and McCutcheon I.E. (1999). Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg, 91, 93–99.

    Article  PubMed  CAS  Google Scholar 

  • Fuh G., Cunningham B.C., Fukunaga R., Nagata S., Goeddel D.V. and Wells J.A. (1992). Rational design of potent antagonists to the human growth hormone receptor. Science, 256, 1677–1680.

    Article  PubMed  CAS  Google Scholar 

  • Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group (2001). The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology, 108, 2266–2272.

    Article  Google Scholar 

  • Hankinson S.E., Willett W.C., Colditz G.A., Hunter DJ., Michaud D.S., Deroo B., Rosner B., Speizer RE. and Pollak M. (1998). Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 351, 1393–1396.

    Article  PubMed  CAS  Google Scholar 

  • Hansen A.P. and Johansen K. (1970). Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia, 6, 27–33.

    Article  PubMed  CAS  Google Scholar 

  • Herman-Bonert V.S., Zib K., Scarlett J.A. and Melmed S. (2000). Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab, 85, 2958–2961.

    Article  PubMed  CAS  Google Scholar 

  • Ho K.K. (2001). Place of pegvisomant in acromegaly. Lancet, 358, 1743–1744.

    Article  PubMed  CAS  Google Scholar 

  • Khandwala H.M., McCutcheon I.E., Flyvbjerg A. and Friend K.E. (2000). The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev, 21, 215–244.

    Article  PubMed  CAS  Google Scholar 

  • Lesniak M.A., Roth J., Görden P. and Gavin J.R. III (1973). Human growth hormone radioreceptor assay using cultured human lymphocytes. Nature New Biol, 241, 20–22.

    PubMed  CAS  Google Scholar 

  • Lundbaek K., Jensen V.A., Olsen TS., Orskov H., Christensen N.J., Johansen K., Hansen A.P. and Osterby R. (1970). Growth hormone and diabetic angiopathy. Lancet, 2, 472.

    PubMed  CAS  Google Scholar 

  • Ma J., Pollak M.N., Giovannucci E., Chan J.M., Tao Y., Hennekens CH. and Stampfer M.J. (1999). Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst, 91, 620–625.

    Article  PubMed  CAS  Google Scholar 

  • McCutcheon I.E., Flyvbjerg A., Hill H., Li J., Bennett W.F., Scarlett J.A. and Friend K.E. (2001). Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg, 94, 487–492.

    Article  PubMed  CAS  Google Scholar 

  • Melmed S. (1990). Acromegaly. N Engl J Med, 322, 966–977.

    Article  PubMed  CAS  Google Scholar 

  • Melmed S. (2001). Acromegaly and cancer: not a problem? J Clin Endocrinol Metab, 86, 2929–2934.

    Article  PubMed  CAS  Google Scholar 

  • O’Dell S.D. and Day I.N. (1998). Insulin-like growth factor II (IGF-II). Int J Biochem Cell  Biol, 30, 767–771.

    Article  PubMed  Google Scholar 

  • Ohlsson C, Bengtsson B.A., Isaksson O.G., Andreassen TT and Slootweg M.C. (1998). Growth hormone and bone. Endocr Rev, 19, 55–79.

    Article  PubMed  CAS  Google Scholar 

  • Orme S.M., McNally R.J., Cartwright R.A. and Belchetz P.E. (1998). Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab, 83, 2730–2734.

    Article  PubMed  CAS  Google Scholar 

  • Osborne C.K., Clemmons D.R. and Arteaga CL. (1990). Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Mol Biol, 37, 805–809.

    Article  PubMed  CAS  Google Scholar 

  • Pollak M., Blouin M.J., Zhang J.C and Kopchick J.J. (2001). Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer, 85, 428–430.

    Article  PubMed  CAS  Google Scholar 

  • Rodvold K. A. and van der Lely A. J. (1999). Pharmacokinetics and pharmacodynamics of B2036PEG, a novel growth hormone receptor antagonist, in acromegalic subjects. The Endocrine Society 81st Annual Meeting. June 12–15 1999, San Diego, CA, Abstract P1-049.

    Google Scholar 

  • Segev Y., Landau D., Rasch R., Flyvbjerg A. and Phillip M. (1999). Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J Am Soc Nephrol, 10, 2374–2381.

    PubMed  CAS  Google Scholar 

  • Smith L.E., Kopchick J.J., Chen W., Knapp J., Kinose E, Daley D., Foley E., Smith R.G. and Schaeffer J.M. (1997). Essential role of growth hormone in ischemia-induced retinal neovascularization. Science, 276, 1706–1709.

    Article  PubMed  CAS  Google Scholar 

  • Theill L.E. and Karin M. (1993). Transcriptional control of GH expression and anterior pituitary development. Endocr Rev,14, 670–689.

    PubMed  CAS  Google Scholar 

  • Thorner M.O., Strasburger C.J.,Wu Z., Straume M., Bidlingmaier M., Pezzoli S.S., Zib K., Scarlett J.C. and Bennett W.E. (1999). Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036- PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab, 84, 2098–2103.

    Article  PubMed  CAS  Google Scholar 

  • Trainer P.J., Drake W.M., Katznelson L., Freda P.U., Herman-Bonert V., van der Lely A.J., Dimaraki E.V., Stewart P.M., Friend K.E., Vance M.L., Besser G.M., Scarlett J.A., Thorner M.O., Parkinson C., Klibanski A., Powell J.S., Barkan A.L., Sheppard M.C., Malsonado M., Rose D.R., Clemmons D.R., Iohannsson G., Bengtsson B.A., Stavrou S., Kleinberg D.L., Cook D.M., Phillips L.S., Bidlingmaier M., Strasburger C.T., Hackett S., Zib K., Bennett W.E and Davis R.J. (2000). Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med, 342, 1171–1177.

    Article  PubMed  CAS  Google Scholar 

  • Utiger R.D. (2000). Treatment of acromegaly. N Engl J Med, 342, 1210–1211.

    Article  PubMed  CAS  Google Scholar 

  • van der Lely A.J., Hutson R.K., Trainer P.J., Besser G.M., Barkan A.L., Katznelson L., Klibanski A., Herman-Bonert V., Melmed S., Vance M.L., Freda P.U., Stewart P.M., Friend K.E., Clemmons D.R., Johannsson G., Stavrou S., Cook D.M., Phillips L.S., Strasburger C.J., Hackett S., Zib K.A., Davis R.J., Scarlett J.A. and Thorner M.O. (2001a). Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, 358, 1754–1759.

    Article  Google Scholar 

  • van der Lely A.J., Muller A., Janssen J.A., Davis R.J., Zib K.A., Scarlett J.A. and Lamberts S.W. (2001b). Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab, 86, 478–481.

    Article  Google Scholar 

  • Veldhuis J.D., Bidlingmaier M., Wu Z. and Strasburger C.J. (2000). A selective recombinant human (rh) GH-receptor antagonist fails to impede metabolic removal of endogenous or exogenous GH in healthy adults: evidence that the GH receptor does not participate primarily in the in vivo GH elimination process. 11th International Congress of Endocrinology 2000, Sydney, Australia, p. 405.

    Google Scholar 

  • Yde H. (1969). Abnormal growth hormone response to ingestion of glucose in juvenile diabetics. Acta Med Scand, 186, 499–504.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. J. van der Lely
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, University of Milan, Milan, Italy

    Eugenio E. Müller

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Italia

About this paper

Cite this paper

van der Lely, A.J. (2003). GH Receptor Antagonists: Basic Knowledge and Clinical Perspectives. In: Müller, E.E. (eds) Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance. Springer, Milano. https://doi.org/10.1007/978-88-470-2085-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2085-6_10

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-2170-9

  • Online ISBN: 978-88-470-2085-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation